Workflow
Adjust
icon
Search documents
INVESTOR ALERT: Investigation of RxSight, Inc. (RXST) Announced by Holzer & Holzer, LLC
GlobeNewswire News Room· 2025-07-11 19:10
ATLANTA, July 11, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) complied with federal securities laws. On July 8, 2025, RxSight announced select preliminary financial results for the second quarter 2025 and revised full-year 2025 guidance, revealing declines in revenue, Light Delivery Devices sales, and usage of Light Adjustable Lenses. Following this news, the price of the Company’s stock dropped.  If you purchased RxSight s ...
Johnson Fistel Begins Investigation on Behalf of RxSight, Inc. (RXST) Shareholders
GlobeNewswire News Room· 2025-07-11 14:12
SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP is investigating whether RxSight, Inc. (NASDAQ: RXST), or any of its executive officers, violated federal securities laws by making false or misleading statements or failing to disclose material information to investors. What if I purchased RXST securities?If you purchased RxSight securities and suffered losses on your investment, you may be eligible to participate in our investigation. To join, please click here: ...
Jewett-Cameron to Report Fiscal 2025 Third Quarter Operational and Financial Results on July 14, 2025
Globenewswire· 2025-07-10 20:15
NORTH PLAINS, Ore., July 10, 2025 (GLOBE NEWSWIRE) -- Jewett-Cameron Trading Company Ltd. (“Jewett-Cameron”) (Nasdaq: JCTC), a company committed to innovative products that enrich outdoor spaces, will report its operational and financial results for its fiscal 2025 third quarter, after the market close on Monday, July 14, 2025. The Company has scheduled a webcast that same day, Monday, July 14, 2025, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session. Webcast Details ...
RxSight, Inc. Announces Preliminary Second Quarter 2025 Revenue and Revised 2025 Guidance
Globenewswire· 2025-07-08 20:05
ALISO VIEJO, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary financial results for the second quarter 2025 and revised full-year 2025 guidance. The Company will host a conference call on Tuesday, July 8, 2025, at 5:00 p.m. Eastern Time. Preliminary Second Quarter 2025 Results Preliminary second quarter 2025 revenue is ...
ARMOUR Residential REIT, Inc. Confirms July 2025 Common Share and Q3 2025 Series C Preferred Share Dividends
Globenewswire· 2025-07-01 20:15
VERO BEACH, Florida, July 01, 2025 (GLOBE NEWSWIRE) -- ARMOUR Residential REIT, Inc. (NYSE: ARR and ARR-PRC) (“ARMOUR” or the “Company”) today confirmed the July 2025 cash dividend for the Company's Common Stock, consistent with the previous guidance which the Company released on June 24, 2025. The Company also confirmed the Q3 2025 monthly cash dividend rate for the Company's Series C Preferred Stock. July 2025 Common Stock Dividend Information Month Dividend Holder of Record Date Payment DateJuly 2025 $0. ...
ARMOUR Residential REIT, Inc. Announces Guidance for July 2025 Dividend Rate per Common Share
Globenewswire· 2025-06-24 20:15
Core Viewpoint - ARMOUR Residential REIT, Inc. has announced a cash dividend of $0.24 per Common share for July 2025, with the holder of record date set for July 15, 2025, and payment date on July 30, 2025 [1][2]. Dividend Information - The July 2025 cash dividend is $0.24 per Common share [2]. - The holder of record date is July 15, 2025, and the payment date is July 30, 2025 [2]. Tax Matters - ARMOUR is taxed as a real estate investment trust (REIT) and must distribute substantially all of its ordinary REIT taxable income to maintain this status [3]. - Dividends exceeding current tax earnings and profits for the year are generally not taxable to common stockholders [3]. - The board of directors determines actual dividends based on various factors including operational results, cash flows, financial condition, and market conditions [3]. Company Overview - ARMOUR primarily invests in fixed-rate residential, adjustable-rate, and hybrid adjustable-rate residential mortgage-backed securities issued or guaranteed by U.S. Government-sponsored enterprises [4]. - The company is externally managed and advised by ARMOUR Capital Management LP, which is registered with the SEC [4].
ARMOUR Residential REIT, Inc. Announces June 2025 Dividend Rate Per Common Share
Globenewswire· 2025-05-29 20:15
VERO BEACH, Florida, May 29, 2025 (GLOBE NEWSWIRE) -- ARMOUR Residential REIT, Inc. (NYSE: ARR and ARR-PRC) (“ARMOUR” or the “Company”) today announced the June 2025 cash dividend for the Company's Common Stock. June 2025 Common Stock Dividend Information Month Dividend Holder of Record Date Payment DateJune 2025 $0.24 June 16, 2025 June 27, 2025 Certain Tax Matters ARMOUR has elected to be taxed as a real estate investment trust (“REIT”) for U.S. Federal income tax purposes. In order to maintain thi ...
Jewett-Cameron Trading Company (JCTC) 2025 Conference Transcript
2025-05-29 17:30
Summary of Jewett-Cameron Trading Company (JCTC) Conference Call Company Overview - Jewett-Cameron Trading Company (JCTC) is a small-cap company with significant growth potential, focusing on durable markets and functional products [3][4] - The company has a 70-year history and is listed on NASDAQ, primarily offering fencing, pet containment, and sustainable home products [4] Core Business and Product Offerings - JCTC is undergoing a strategic transformation, evolving from a lean operation to a growth-oriented platform with product leadership in outdoor living and home improvement [5] - Key product categories include: - **Fencing Products**: Includes fence boards, pickets, steel access accessories, and composite EuroFence products [8] - **Pet Containment**: Focuses on durable solutions like welded wire and chain link dog kennels [8] - **Sustainable Products**: Compostable and post-consumer recycled products, including bags for waste [8] - **Greenwood**: A subsidiary specializing in industrial wood products, particularly proprietary plywood for transit buses [8] Market Position and Growth Strategy - JCTC has established strong retail relationships with major retailers like Home Depot, Lowe's, and Costco, enhancing shelf presence and growth momentum [6] - The company is actively transitioning to growth mode by optimizing pricing, expanding distribution, and reducing overhead [8] - The introduction of innovative products, such as the lifetime steel post and adjustable gates, has driven significant sales growth [10][12] Financial Position - JCTC is trading at a steep discount to book value, has no long-term debt, and possesses a valuable 11.6-acre property that could enhance equity upon sale [7] - The company has reduced inventory levels to align with growth plans, improving cash flow and operational efficiency [16][17] Supply Chain and Tariff Mitigation - JCTC has diversified its supply chain to include sourcing from countries like Vietnam, Bangladesh, Malaysia, and Indonesia, reducing dependency on China [21][22] - The company has implemented a comprehensive multisourcing strategy to mitigate tariff impacts, particularly the 25% global steel tariff [21][22] - Ongoing landed cost comparisons and dual tooling strategies are in place to maintain competitive pricing and ensure supply continuity [25][26] Customer Response and Pricing Strategy - Customers have responded positively to recent price adjustments, which have been modest due to proactive sourcing strategies [27][28] - JCTC aims to maintain competitive pricing while ensuring product quality and reliability, reinforcing its position as a trusted supplier [28] Property Sale and Future Outlook - The company is selling an 11-acre property in Oregon, which has faced a slower sales timeline due to market uncertainties and zoning constraints [30][31] - The property is valued at $9 million, with significant potential upside upon sale [32] - JCTC envisions a dominant presence in the fencing market and plans to expand its product range and distribution channels over the next five to ten years [33][34] Final Takeaways - JCTC is executing a focused strategy with strong momentum in key product categories and strategic sourcing initiatives [36] - The management team is committed to creating value for shareholders, making it an opportune time for investors to consider the company [36]
RxSight, Inc. to Participate in the Stifel 2025 Virtual Ophthalmology Forum
Globenewswire· 2025-05-20 20:10
Core Insights - RxSight, Inc. is an ophthalmic medical device company focused on providing customized vision solutions for patients post-cataract surgery [3] - The company will participate in the Stifel Virtual Ophthalmology Forum on May 27, 2025, featuring a fireside chat with management [2] Company Overview - RxSight offers the RxSight® Light Adjustable Lens system, which includes the Light Adjustable Lens (LAL®/LAL+®) and the Light Delivery Device (LDD™), the first adjustable intraocular lens technology available commercially [3] - This technology allows for post-surgery adjustments, enabling personalized vision outcomes for cataract surgery patients [3] Event Participation - The management of RxSight is scheduled for a fireside chat at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time on May 27, 2025 [2] - A live and archived webcast of the presentation will be accessible on the company's investor relations website [2]
RxSight (RXST) 2025 Conference Transcript
2025-05-14 23:40
Summary of RxSight (RXST) Q1 2025 Conference Call Company Overview - **Company**: RxSight (RXST) - **Industry**: Medical Technology, specifically focusing on ophthalmology and cataract surgery Key Points Q1 2025 Financial Performance - Q1 revenue grew by **28% year-over-year**, but fell short of market expectations [3][17] - LAL (Light Adjustable Lens) sales were impacted by macroeconomic factors, while LDD (Light Adjustable Lens Delivery) sales exceeded expectations [3][11] Macroeconomic Impact - The demographic typically resistant to economic downturns (60+ age group) showed signs of deferring treatments due to equity market shocks and changes in administration [5][6] - Patients cited economic concerns as reasons for deferring or canceling surgeries, a trend not seen since COVID-19 [6][14] Market Dynamics - The premium IOL market has been flat to declining, with RxSight's growth primarily driven by LAL sales [9][10] - The company noted a generational shift in ophthalmology, with a growing emphasis on work-life balance among physicians, impacting practice productivity [8][9] LDD Sales Performance - LDD sales remained strong throughout 2024 and continued into Q1 2025, indicating a robust demand for capital equipment [11][12] - LALs offer significantly better outcomes for patients compared to monofocal lenses, which incentivizes practices to adopt them despite economic pressures [12][13] Future Expectations - The company anticipates a **20% growth in LAL sales** for Q2 2025, with expectations of a stronger second half of the year as economic conditions stabilize [17][19] - Guidance for 2025 is wide-ranging, reflecting uncertainty in consumer behavior and macroeconomic conditions [20][21] International Market Opportunities - Recent approvals in international markets (e.g., Korea, EU) are expected to contribute modestly to sales, with a focus on building clinical data and key opinion leaders in these regions [28][44][49] Education and Support Initiatives - RxSight plans to enhance education and marketing support for practices to optimize the implementation of their technology, driven by feedback from customers [30][32] - The company aims to address utilization challenges and improve patient outcomes through systematic dissemination of information [32][34] Utilization Trends - There has been a slowdown in the growth of LDD procedures, attributed to macroeconomic factors affecting patient confidence [36][38] - The installed base of LDDs is growing, but the ramp-up in utilization has not met expectations compared to previous years [36][40] Physician Demographics - The adoption of RxSight's technology spans a range of physician experience levels, with younger doctors more inclined to adopt new technologies for career advancement [41][42] Conclusion - RxSight is navigating a challenging macroeconomic environment while maintaining strong sales in LDDs and LALs. The company is focused on education, international expansion, and adapting to market dynamics to drive future growth [44][49]